2026 Global: Alzheimer'S Disease Patients Market -Competitive Review (2032) report
Description
The 2026 Global: Alzheimer'S Disease Patients Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease patients market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease patients market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Biogen and Eisai lead the Alzheimer’s market with their amyloid‑targeting antibody Leqembi (lecanemab), which revived confidence in disease‑modifying therapies after regulatory approval and remains a commercial and clinical anchor for both companies in 2023–2025 as they expand indications and delivery formats to improve access and safety. Eli Lilly is a second major player, commercializing Kisunla (donanemab) and advancing follow‑on anti‑amyloid candidates and subcutaneous formulations intended to compete on efficacy, safety and ease of administration, with analysts projecting substantial peak sales potential for its Alzheimer’s portfolio. Roche and Genentech are important market participants through broad neurology pipelines and diagnostics capabilities that support patient identification for targeted therapies, leveraging biomarker research to complement therapeutic development. Johnson & Johnson strengthened its presence via large strategic acquisitions in neurology, including the 2025 purchase of Intra‑Cellular Therapies to add oral small molecules for agitation and psychosis in Alzheimer’s, signaling diversification beyond monoclonal antibodies into symptomatic and psychiatric symptom management. AbbVie has moved aggressively into Alzheimer’s through acquisitions such as Aliada Therapeutics and by in‑licensing novel antibody approaches (e.g., anti‑3pE‑Aβ candidates), aiming to combine innovative delivery technologies with established commercialization infrastructure. Sanofi has expanded its neuroscience footprint by investing in and acquiring Vigil Neuroscience to obtain TREM2 agonists and other microglia‑targeted programs, reflecting a strategy to target innate immune mechanisms and earlier disease biology. AstraZeneca and Merck are notable for broad late‑stage R&D and platform capabilities, with both companies exploring repurposed agents and metabolic/GLP‑1 pathways (e.g., semaglutide trials) that could address disease modification or symptomatic benefit in certain AD populations. Smaller specialized firms with outsized scientific influence include TauRx Pharmaceuticals and Anavex Life Sciences, which pursue non‑amyloid mechanisms such as tau aggregation inhibition (HMTM) and Sigma‑1 receptor modulation (blarcamesine), respectively, and have presented important late‑stage or long‑term data at key conferences that sustain investor and clinical interest. Finally, a diverse group of biotech innovators and mid‑sized companies (examples cited across the 2025 pipeline) — ranging from AriBio with oral agents in Phase III to many firms developing cognitive enhancers, neuropsychiatric symptom treatments, and novel delivery technologies — constitute the tenth component of the market by supplying differentiated mechanisms, trial diversity and partnering opportunities that large pharma either acquires or licenses to round out commercial portfolios.
Together these ten company categories shape a market now characterized by renewed M&A activity, growing numbers of Phase II–III disease‑modifying candidates, increasing emphasis on biomarker‑guided patient selection, and competition between intravenous, subcutaneous and oral modalities to improve access and safety for people living with Alzheimer’s disease.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease patients market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease patients market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Biogen and Eisai lead the Alzheimer’s market with their amyloid‑targeting antibody Leqembi (lecanemab), which revived confidence in disease‑modifying therapies after regulatory approval and remains a commercial and clinical anchor for both companies in 2023–2025 as they expand indications and delivery formats to improve access and safety. Eli Lilly is a second major player, commercializing Kisunla (donanemab) and advancing follow‑on anti‑amyloid candidates and subcutaneous formulations intended to compete on efficacy, safety and ease of administration, with analysts projecting substantial peak sales potential for its Alzheimer’s portfolio. Roche and Genentech are important market participants through broad neurology pipelines and diagnostics capabilities that support patient identification for targeted therapies, leveraging biomarker research to complement therapeutic development. Johnson & Johnson strengthened its presence via large strategic acquisitions in neurology, including the 2025 purchase of Intra‑Cellular Therapies to add oral small molecules for agitation and psychosis in Alzheimer’s, signaling diversification beyond monoclonal antibodies into symptomatic and psychiatric symptom management. AbbVie has moved aggressively into Alzheimer’s through acquisitions such as Aliada Therapeutics and by in‑licensing novel antibody approaches (e.g., anti‑3pE‑Aβ candidates), aiming to combine innovative delivery technologies with established commercialization infrastructure. Sanofi has expanded its neuroscience footprint by investing in and acquiring Vigil Neuroscience to obtain TREM2 agonists and other microglia‑targeted programs, reflecting a strategy to target innate immune mechanisms and earlier disease biology. AstraZeneca and Merck are notable for broad late‑stage R&D and platform capabilities, with both companies exploring repurposed agents and metabolic/GLP‑1 pathways (e.g., semaglutide trials) that could address disease modification or symptomatic benefit in certain AD populations. Smaller specialized firms with outsized scientific influence include TauRx Pharmaceuticals and Anavex Life Sciences, which pursue non‑amyloid mechanisms such as tau aggregation inhibition (HMTM) and Sigma‑1 receptor modulation (blarcamesine), respectively, and have presented important late‑stage or long‑term data at key conferences that sustain investor and clinical interest. Finally, a diverse group of biotech innovators and mid‑sized companies (examples cited across the 2025 pipeline) — ranging from AriBio with oral agents in Phase III to many firms developing cognitive enhancers, neuropsychiatric symptom treatments, and novel delivery technologies — constitute the tenth component of the market by supplying differentiated mechanisms, trial diversity and partnering opportunities that large pharma either acquires or licenses to round out commercial portfolios.
Together these ten company categories shape a market now characterized by renewed M&A activity, growing numbers of Phase II–III disease‑modifying candidates, increasing emphasis on biomarker‑guided patient selection, and competition between intravenous, subcutaneous and oral modalities to improve access and safety for people living with Alzheimer’s disease.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.